Panelists discuss how generalized pustular psoriasis (GPP), while rare, presents with distinctive widespread sterile pustules on erythematous skin, requires prompt medical intervention, and differs significantly from more common plaque psoriasis in its clinical presentation, triggers, and treatment approaches.
An expert discusses the qualities of genetic tests that are most important to clinicians seeking precise and reliable results for melanoma diagnosis and prognosis, and reviews the 31-gene expression profile (GEP) test, highlighting its ability to classify melanoma risk into 1A, 1B, 2A, and 2B, with 1A patients showing higher melanoma-specific survival (MSS) and overall survival (OS), while 1B/2A and 2B classifications serve as independent predictors of MSS and OS, noting that patients who underwent 31-GEP testing had lower mortality compared with untested patients.
An expert discusses the patient demographics and clinical features used in traditional staging and risk classification of melanoma and squamous cell carcinoma (SCC), examining how staging systems from organizations like the American Joint Committee on Cancer (AJCC) and National Comprehensive Cancer Network (NCCN) align in risk classification, the challenges of relying solely on clinical features for prognosis, and the importance of accurate risk staging in guiding treatment decisions for these cancers.
Panelists discuss how health care providers can effectively communicate the benefits and risks of JAK inhibitors to patients with atopic dermatitis while addressing safety concerns and establishing realistic treatment expectations.
Panelists discuss how IL-17 inhibitors differ in their targets within the IL-17 pathway. Secukinumab and ixekizumab block IL-17A, reducing inflammation in psoriasis and arthritis. Brodalumab inhibits IL-17RA, affecting multiple IL-17 cytokines, but carries suicide risk warnings. Bimekizumab targets IL-17A and IL-17F, potentially enhancing efficacy but with added risk of infections. These differences impact efficacy, safety, and patient selection in inflammatory diseases.
Panelists discuss how IL-17 is a key pro-inflammatory cytokine in plaque psoriasis pathogenesis. It stimulates keratinocyte proliferation, promotes neutrophil recruitment, induces antimicrobial peptides, and up-regulates other inflammatory mediators, creating a self-perpetuating inflammatory cascade in lesional skin.
Panelists discuss how clinicians can interpret and apply the JAK inhibitor class boxed warning to make informed treatment decisions while weighing potential risks against therapeutic benefits for individual patients.
Nail psoriasis affects 50% of plaque psoriasis patients, making effective treatments crucial.
An expert discusses how dermatologists guide patients in selecting sunscreens based on skin type (fair skin, skin of color, sensitive skin), coexisting conditions, and environmental exposure (blue light, heavy sun). They recommend sun protection factor (SPF) levels and key ingredients and address adherence barriers. Beyond sunscreen, protective clothing, antioxidants, and physical blockers help shield against visible light and infrared radiation.
An expert discusses how oxidative stress accelerates skin aging by damaging cells through free radicals, which form from UV exposure. Antioxidants such as vitamins C and E, niacinamide, and polyphenols counteract this damage. Combining antioxidants with sunscreen enhances protection, reducing free radical formation and optimizing skin health.
An expert discusses a comprehensive review of treatment options for a 32-year-old woman with alopecia areata, covering baricitinib dosing (4 mg initially), monitoring requirements vs ritlecitinib, expected outcomes, and considerations for topical immunotherapy vs JAK inhibitors.
An expert discusses a 32-year-old woman with alopecia areata affecting eyebrows/eyelashes. Treatment options include topical/intralesional steroids, minoxidil, prostaglandin analogues, JAK inhibitors, and cosmetic approaches.
Tomassian noted unrealistic beauty standards fueled by social media filters and edited images have led to distorted expectations.
Christopher B. Zachary, MBBS, MRCP, FRCP, shares insights in apoptosis-based skin care treatment.
Panelists discuss how JAK inhibitors demonstrate significant efficacy in treating atopic dermatitis while examining their safety profiles and optimal positioning within the therapeutic landscape.
Panelists discuss how varying degrees of JAK selectivity in targeted therapies affect treatment outcomes, safety profiles, and therapeutic decision-making in atopic dermatitis management.
Elizabeth Berry, MD, FAAD, reviewed dysplastic nevi as risk markers and highlighted the need for more data on severe cases at AAD 2025.
Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C discuss the NEA's expanded eczema visual guide and upcoming Chicago event to support diverse patient communities.
By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.
The panelist discusses how the therapeutic options for atopic dermatitis have expanded significantly with the emergence of targeted biologics, oral agents, and refined topical treatments, transforming the management approach for patients across the disease spectrum.
Christopher Bunick, MD, PhD, reviewed the evolving role of antibiotics, emphasizing antibiotic stewardship, the gut-skin connection, and the importance of narrow-spectrum antibiotics at AAD 2025.
An expert discusses how UV radiation causes DNA damage, accelerating skin aging and cancer risk. Visible light and infrared radiation induce oxidative stress and hyperpigmentation, especially in darker skin tones. Conventional sunscreens shield against UV radiation but offer limited visible light and infrared protection. Mineral filters (zinc oxide, titanium dioxide) provide broad coverage, while chemical filters (oxybenzone, avobenzone) absorb UV radiation but lack efficacy against visible and infrared radiation.
An expert discusses how UV radiation makes up about 7% of the sun’s energy and penetrates the skin, causing aging, hyperpigmentation, and inflammation. Visible light and infrared radiation contribute to skin damage, with blue light being more harmful than red light due to its deeper penetration.
Wendy Smith Begolka, MBS, and Renata Block, MMS, PA-C, discuss redefining eczema flares to align clinical and patient perspectives.
Renata Block, MMS, PA-C, speaks with Wendy Smith Begolka, MBS, of the National Eczema Association about NEA’s strategic efforts in community outreach, health care provider engagement, and patient education.
Christopher Bunick, MD, PhD, discussed how to interpret recent benzene research as clinicians await regulatory guidance for benzoyl peroxide.
Anabela Cardoso, MD, discussed lebrikizumab’s efficacy in improving itch, skin pain, sleep disturbance, and long-term management in atopic dermatitis.
An expert discusses how alopecia areata significantly affects adolescent mental health. Treatment with ritlecitinib requires proper severity assessment via Severity of Alopecia Tool (SALT) score, clear communication of realistic timelines and goals, careful monitoring, and discussion of potential adverse effects. Long-term adherence is crucial for maintaining results.
An expert discusses how treatment for this adolescent boy with severe alopecia areata must balance efficacy with age-appropriate safety, considering psychological impact, growth/development factors, and family preferences while selecting among topical, intralesional, systemic, or emerging biologic options.
Lisa M. Arkin, MD, shared how early laser treatment and multidisciplinary approaches improves outcomes for vascular anomalies.
